Loading…
Quoin Pharmaceuticals, Ltd. is projected to rise to $5.87 by 2027, a +32% move from its current price of $4.45. QNRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $4.20 | $4.46 | $4.73 | +0.18% |
| Jul 15 | $4.11 | $4.47 | $4.85 | +0.36% |
| Jul 16 | $4.04 | $4.47 | $4.96 | +0.54% |
| Jul 17 | $3.98 | $4.48 | $5.04 | +0.72% |
| Jul 18 | $3.94 | $4.49 | $5.12 | +0.90% |
| Jul 19 | $3.89 | $4.50 | $5.20 | +1.08% |
| Jul 20 | $3.86 | $4.51 | $5.27 | +1.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.86 | $4.51 | $5.27 | +1.27% |
| Week 2 | $3.66 | $4.56 | $5.69 | +2.55% |
| Week 3 | $3.53 | $4.62 | $6.05 | +3.84% |
| Week 4 | $3.43 | $4.68 | $6.39 | +5.16% |
| Week 5 | $3.34 | $4.74 | $6.72 | +6.49% |
| Week 6 | $3.27 | $4.80 | $7.03 | +7.83% |
| Week 7 | $3.22 | $4.86 | $7.34 | +9.20% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Quoin Pharmaceuticals, Ltd. is a late-stage specialty pharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases in the United States. The lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome, phase 1 to treat peeling skin syndrome, and in pre-clinical stage to treat SAM syndrome and ichthyosis.
It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd.
was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Quoin Pharmaceuticals, Ltd. (QNRX) is currently priced at $4.55 per share and has a market capitalization of $9.14M, with a market rank of 4860.
The forecast landscape outlines a multi-year price path, with a 2026 average of $4.55 and a 2026 min of $3.25, max of $6.97, reflecting a neutral near-term sentiment. The long-run forecast shows bullish momentum with average prices rising toward the mid-to-high single digits and beyond, culminating in an average of $15.79 by 2050 and a max of $36.32, with a high level of positive sentiment in the distant horizon.
A major floor 45.1% below — a decisive break under it would weaken the trend.
The nearest floor, 27.0% below — buyers have tended to step in here.
The nearest ceiling, 13.7% above — a clean break opens room to run.
A major ceiling 108.3% above — clearing it would confirm fresh momentum.
Key QNRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of QNRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.65 | Sell | $4.60 | Sell |
| MA 10 | $4.64 | Sell | $4.58 | Sell |
| MA 20 | $4.47 | Sell | $4.59 | Sell |
| MA 50 | $5.03 | Sell | $5.09 | Sell |
| MA 100 | $6.23 | Sell | $6.24 | Sell |
| MA 200 | $9.17 | Sell | $9.39 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.23 | Neutral |
| Stoch RSI (14) | 74.87 | Neutral |
| CCI (20) | -4.56 | Neutral |
| Williams %R (14) | -24.53 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | 36.92 | Buy |
| Bollinger %B (20,2) | 0.49 | Neutral |
| Stochastic %K (14) | 75.47 | Neutral |
| TRIX (15) | -0.47 | Sell |
| Awesome (5,34) | 0.06 | Buy |
| Ultimate (7,14,28) | 35.21 | Neutral |
| Momentum (10) | 0.25 | Buy |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 4.65 | Sell |
| ADX (14) | 12.20 | Neutral |
| ATR (14) | 0.22 | Info |
Sentiment is NEUTRAL in the near term with an RSI14 of 50. The SMA50 is $5.22 and the SMA200 is $9.30, indicating the recent price is around the intermediate moving averages.
The 30-day range runs from a low of $2.83 to a high of $7.31, showing notable intra-month volatility. Support sits at $3.25 and resistance at $5.79, forming a framework for near-term price action. The asset also exhibits annualized volatility of 100%, underscoring substantial price fluctuations in the short run.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.25 | $4.45 | $6.83 | 0% | Neutral | |
| $4.26 | $5.87 | $8.75 | +32% | Bullish | |
| $4.49 | $6.58 | $10.45 | +48% | Bullish | |
| $4.76 | $7.35 | $12.25 | +65% | Bullish | |
| $3.56 | $5.76 | $10.00 | +30% | Bullish | |
| $3.09 | $5.23 | $9.39 | +17% | Neutral | |
| $3.39 | $5.97 | $11.06 | +34% | Bullish | |
| $3.56 | $6.53 | $12.44 | +47% | Bullish | |
| $4.38 | $8.36 | $16.32 | +88% | Bullish | |
| $4.34 | $8.62 | $17.22 | +94% | Bullish | |
| $4.77 | $10.60 | $23.26 | +138% | Bullish | |
| $7.20 | $16.00 | $36.80 | +260% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.25 | $4.45 | $5.46 | +0.00% |
| August 2026 | $4.07 | $4.93 | $6.22 | +10.88% |
| September 2026 | $4.27 | $5.24 | $6.75 | +6.23% |
| October 2026 | $3.98 | $4.95 | $6.49 | -5.55% |
| November 2026 | $3.84 | $4.82 | $6.41 | -2.55% |
| December 2026 | $4.00 | $5.07 | $6.83 | +5.07% |
Click any year to see its month-by-month QNRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, QNRX is projected to trade between $3.25 and $6.83, averaging $4.45 — a potential gain of 0% from today's $4.45. Price action looks broadly range-bound.
Quoin Pharmaceuticals, Ltd.'s 2027 outlook centres on $5.87, within a $4.26 to $8.75 range. That is up +32% on the projected 2026 average. That marks a +32% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, QNRX could reach as high as $10.45, with a base case around $6.58 and support toward $4.49 — roughly +48% from $4.45. Momentum favours further upside here.
Expect QNRX to range from $4.76 to $12.25 through 2029. The $7.35 average target implies a +65% move from current prices. That is up +12% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The QNRX price prediction for 2030 points to an average of $5.76 (low $3.56, high $10.00) — a potential gain of +30% on today's $4.45. Momentum favours further upside here.
In 2031, QNRX is projected to trade between $3.09 and $9.39, averaging $5.23 — a potential gain of +17% from today's $4.45. That is -9% versus the projected 2030 average. A consolidation phase looks the most probable path here.
Quoin Pharmaceuticals, Ltd.'s 2032 outlook centres on $5.97, within a $3.39 to $11.06 range. That is up +14% on the projected 2031 average. That marks a +34% change versus current levels. Momentum favours further upside here.
By 2033, QNRX could reach as high as $12.44, with a base case around $6.53 and support toward $3.56 — roughly +47% from $4.45. Buyers look set to stay in control over this stretch.
Expect QNRX to range from $4.38 to $16.32 through 2034. The $8.36 average target implies a +88% move from current prices. That is up +28% on the projected 2033 average. Momentum favours further upside here.
The QNRX price prediction for 2035 points to an average of $8.62 (low $4.34, high $17.22) — a potential gain of +94% on today's $4.45. Buyers look set to stay in control over this stretch.
In 2040, QNRX is projected to trade between $4.77 and $23.26, averaging $10.60 — a potential gain of +138% from today's $4.45. That is up +23% on the projected 2035 average. Momentum favours further upside here.
Quoin Pharmaceuticals, Ltd.'s 2050 outlook centres on $16.00, within a $7.20 to $36.80 range. That is up +51% on the projected 2040 average. That marks a +260% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in QNRX today (≈ 224.719101 QNRX) could be worth
$3,595.44
+$2,595.44 (+260%) by 2050 · US Dollar
Based on the average projected QNRX price of $16 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in QNRXwould be worth at today's price.
$1,000 invested in QNRX on Jul 10, 2025 (≈ 110.987789 QNRX) would be worth
$493.9
-$506.1 (-50.6%) today · 0.49× · US Dollar
Based on a QNRX entry price of $9.01 vs. today's $4.45.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.58 | $971.62 | -2.8% |
| 1 month ago | $5.06 | $879.45 | -12.1% |
| 3 months ago | $5.9 | $754.24 | -24.6% |
| 6 months ago | $11.72 | $379.76 | -62.0% |
| 1 year ago | $9.01 | $493.9 | -50.6% |
| All time (5.0y) ago | $85,890 | $0.05 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our QNRX forecast.
Our base-case forecast reaches $8.90 around 2040.
Implied market cap at $8.90: $17.87M
The year-by-year forecast shows a path of gradual upside across the late 2020s and into the 2030s. In 2026, the average price is $4.55 with a min of $3.25 and a max of $6.97, and a neutral sentiment. From 2027 onward, the outlook turns bullish, with 2027 avg $5.87 and 2028 avg $6.81 adding to a rising trend through 2029 at $7.49 and into the 2030s.
By 2030, the average is projected at $5.66 with a max of $9.84 and a min of $3.49, yielding a 24.4 ROI and bullish sentiment. The path extends through 2031 ($5.40 avg, $9.71 max, $3.19 min; ROI 18.7) and 2032 ($6.15 avg, $11.40 max, $3.48 min; ROI 35.2) and 2033 ($6.31 avg, $12.02 max, $3.43 min; ROI 38.6).
In 2034, the forecast jumps to an average of $8.44 with a max of $16.50 and a min of $4.41 (ROI 85.6), followed by 2035 at $8.81 avg, $17.62 max, $4.43 min (ROI 93.7). The bullish trajectory continues to 2040 with an average of $10.87 and a max of $23.88 (ROI 139), and culminates in 2050 with an average of $15.79 and a max of $36.32 (ROI 247.1). These figures assume the given min/avg/max values and reflect the stated sentiment shifts over time.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $5.66 with a min of $3.49 and a max of $9.84; ROI 24.4; sentiment BULLISH.
The forecast shows bullish sentiment in 2027–2050 with positive ROI values (e.g., 29 in 2027, 49.6 in 2028, 64.6 in 2029, 139 in 2040, and 247.1 in 2050). However, 2026 is neutral and these are estimates, not guarantees.
Yes. The 2032 max is $11.40 and the 2033 max is $12.02, with higher maxima in later years (e.g., 2034 max $16.50 and 2050 max $36.32), suggesting a crossing of $10 is possible within the forecast horizon.
The 30-day range is $2.83 to $7.31. RSI14 is 50, the SMA50 is $5.22, and the SMA200 is $9.30. Support is $3.25 and resistance is $5.79, with sentiment labeled NEUTRAL.
Current price is $4.55 and market capitalization is $9.14M, with a market rank of 4860.
Quoin Pharmaceuticals, Ltd. Community Discussion
0Share your Quoin Pharmaceuticals, Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.